April 9 : Immunic's MS R&D Day. Management of Immunic, includingDaniel Vitt , Ph.D., Chief Executive Officer and President,Andreas Muehler , M.D., M.B.A. Chief Medical Officer andHella Kohlhof , Ph.D, Chief Scientific Officer, will be joined by renowned key opinion leaders to discuss the latest developments in the MS landscape as well as recent preclinical and clinical data supporting the neuroprotective potential of Immunic's late-stage clinical asset, first-in-class Nurr1 activator, vidofludimus calcium. The MS R&D Day will take place onTuesday, April 9, 2024 , from10:30 am to 12:30 pm PST in-person at theHotel Nikko inSan Francisco . To register, please RSVP by sending an email to: ir@imux.com.April 15-17 : Accelerating Bio-Innovation 2024 UK.Dr. Vitt will participate in one-on-one meetings at this conference inCambridge, England .April 17-18 : Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference.Dr. Vitt will participate in a fireside chat and one-on-one investor meetings at this virtual conference. A webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. An archived replay will be available after the conference.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in corporate events and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the
Contact Information
Immunic, Inc.
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
+1 617 974 8659
kaplan@kogspr.com